CD47-blocking antibody confers metabolic benefits against obesity., PMID:40267910
Innate immune checkpoint SIRPα/CD47 blockade ameliorates silica-induced pulmonary fibrosis by modulating macrophage immunity., PMID:40279943
Multi-Omics Analysis of the Immune Effect of the Engineered Exosome Drug Delivery System in Inducing Macrophage Apoptosis., PMID:40284489
N-deglycosylation targeting chimera (DGlyTAC): a strategy for immune checkpoint proteins inactivation by specifically removing N-glycan., PMID:40289109
Phagocytosis-Activating Nanocomplex Orchestrates Macrophage-Mediated Cancer Immunotherapy., PMID:40289887
Oncolytic adenovirus H101 enhances the anti-tumor effects of PD-1 blockade via CD47 downregulation in tumor cells., PMID:40296909
Cisplatin reduces immunosuppression caused by tumor-associated macrophages through downregulating CD47-SIRPα signaling in glioblastoma., PMID:40300658
CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation., PMID:40307254
TSP-1-CD47-integrin α4β1 axis drives T cell infiltration and synovial inflammation in rheumatoid arthritis., PMID:40308591
Development of a high-throughput TR-FRET assay to identify inhibitors of the FAK-paxillin protein-protein interaction., PMID:40318755
[Crosstalk and the progression of hepatocellular carcinoma]., PMID:40326070
Nanobody-Based PET Imaging of CD47 Expression in Thyroid Carcinoma., PMID:40326602
Engineered Bacterial Biohybrid-Mediated CD47-SIRPα Blockade and HSP90 Inhibition for Enhanced Immuno-Photothermal Therapy., PMID:40331355
Refolding of the recombinant IgV domain of CD47 from E. coli for NMR studies., PMID:40334763
A novel Dual GLP-1/CCK Receptor Agonist Improves Cognitive Performance and Synaptogenesis in the 5 × FAD Alzheimer Mouse Model., PMID:40338455
Oncolytic viruses targeting CD47: a new road to success?, PMID:40341033
LincNEAT1 Encoded-NEAT1-31 Promotes Phagocytosis by Directly Activating the Aurora-A-PI3K-AKT Pathway., PMID:40344649
Cancer vaccine from intracellularly gelated tumor cells functionalized with CD47 blockage and damage-associated molecular pattern exposure., PMID:40345180
Dual targeting of ENPP3 and SIRPα with a bispecific antibody enhances macrophage-mediated immunity in renal cell carcinoma., PMID:40349459
EGFR/STAT3 signaling mediates the upregulation of CD47 in HPV-positive cervical cancer by activating p65 and exosome transporter RAB31., PMID:40353624
The Efficacy of Targeted Monoclonal IgA Antibodies Against Pancreatic Ductal Adenocarcinoma., PMID:40358156
Prognostic value of CD47 overexpression measured by flow cytometry in acute myeloid leukemia., PMID:40369208
Immunotherapy of endometrial cancer via CD47 blockade-mediated macrophage phagocytosis., PMID:40371397
CD47 expression in classic follicular lymphoma is associated with event-free survival., PMID:40374148
Tumor-derived exosomal CCT6A serves as a matchmaker introducing chemokines to tumor-associated macrophages in pancreatic ductal adenocarcinoma., PMID:40374617
USP2 inhibition unleashes CD47-restrained phagocytosis and enhances anti-tumor immunity., PMID:40379682
Long-term engraftment of human stem and progenitor cells for large-scale production of functional immune cells in engineered pigs., PMID:40394219
Pan-cancer analysis of phagocytosis regulators in female-specific cancers: a focus on HMGB2., PMID:40396172
Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy., PMID:40402266
A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity., PMID:40408355
The cytotoxic effect of quercetin-induced apoptosis on lung metastatic cells from giant cell tumor of bone., PMID:40418557
CDC34 suppresses macrophage phagocytic activity and predicts poor response to immune checkpoint inhibitor in cancers., PMID:40419082
CD99: A Key Regulator in Immune Response and Tumor Microenvironment., PMID:40427525
Monoclonal Antibodies Against Myeloid Leukemia Cells: Current Knowledge and Future Directions., PMID:40429716
Novel immunotherapy for gastric cancer: targeting the CD47-SIRPα axis., PMID:40437298
Dual blockade of TNFR2 and CD47 reshape tumor immune microenvironment and improve antitumor effects in colorectal cancer., PMID:40450521
CD200R1-CD200 checkpoint inhibits phagocytosis differently from SIRPα-CD47 to suppress tumor growth., PMID:40461553
Designed gramicidin-inspired stabilized peptide-based therapeutics to potentiate immunotherapy against aggressive kidney cancer., PMID:40485488
Nanoparticle-formulated mRNA encoding engineered multivalent SIRPα-Fc fusion proteins shows robust anti-cancer activity in preclinical models., PMID:40487351
CDH17-targeting CAR-NK cells synergize with CD47 blockade for potent suppression of gastrointestinal cancers., PMID:40487639
Sonodynamic therapy-boosted biomimetic nanoplatform targets ferroptosis and CD47 as vulnerabilities for cancer immunotherapy., PMID:40490790
Targeting MAN1B1 potently enhances bladder cancer antitumor immunity via deglycosylation of CD47., PMID:40493414
Drug repurposing of fostamatinib against cancer via potential cytotoxicity and immune checkpoint regulation., PMID:40510356
PSGL-1 is a phagocytosis checkpoint that enables tumor escape from macrophage clearance., PMID:40512837
Mechanism of EC-EXOs-Derived THBS3 Targeting CD47 to Regulate BMSCs Differentiation to Ameliorate Bone Loss., PMID:40514348
Synaptic pruning genes networks in Alzheimer's disease: correlations with neuropathology and cognitive decline., PMID:40515808
Commentary on "Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors"., PMID:40518291
Multi-tissue single-nucleus RNA-seq reveals cell type-specific regulatory patterns of alternative polyadenylation in pigs., PMID:40523804
SIRPα blockade therapy potentiates immunotherapy by inhibiting PD-L1+ myeloid cells in hepatocellular carcinoma., PMID:40523887
STAT3 inhibition in combination with CD47 blockade inhibits osteosarcoma lung metastasis., PMID:40529368
Increased lymphocyte activation and atherosclerosis in CD47-deficient mice. PMID: 31337788
Combination of CD47 and signal-regulatory protein-alpha constituting the "don't eat me signal" is a prognostic factor in diffuse large B-cell lymphoma. PMID: 32342603
CD47 in xenograft rejection and tolerance induction. PMID: 20723199
Inhibited CD47 gene affects the clearance of acute myelogenous leukemia stem cells. PMID: 30565723
Expression of CD47 antigen in Reed-Sternberg cells as a new potential biomarker for classical Hodgkin lymphoma. PMID: 31359339
A single-valent long-acting human CD47 antagonist enhances antibody directed phagocytic activities. PMID: 32583154
Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice. PMID: 31996683
A homogeneous SIRPalpha-CD47 cell-based, ligand-binding assay: Utility for small molecule drug development in immuno-oncology. PMID: 32240171
CD47 Blockade and Cowpea Mosaic Virus Nanoparticle In Situ Vaccination Triggers Phagocytosis and Tumor Killing. PMID: 30838815
Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy. PMID: 30938231
CD47-ligation induced cell death in T-acute lymphoblastic leukemia. PMID: 29748606
CD47: a new player in phagocytosis and xenograft rejection. PMID: 21258362
Activated CD47 regulates multiple vascular and stress responses: implications for acute kidney injury and its management. PMID: 22874763
Clinicopathological significance of CD47 expression in hepatocellular carcinoma. PMID: 32576628
The macrophage checkpoint CD47 : SIRPalpha for recognition of 'self' cells: from clinical trials of blocking antibodies to mechanobiological fundamentals. PMID: 31431181
Immunotherapeutic Blockade of CD47 Inhibitory Signaling Enhances Innate and Adaptive Immune Responses to Viral Infection. PMID: 32294445
Positive tumour CD47 expression is an independent prognostic factor for recurrence in resected non-small cell lung cancer. PMID: 32830120
CD47 in the Brain and Neurodegeneration: An Update on the Role in Neuroinflammatory Pathways. PMID: 34203368
CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest. PMID: 22774848
TSP1-CD47-SIRPalpha signaling facilitates the development of endometriosis by mediating the survival of ectopic endometrium. PMID: 32196807
CD47: a new target in cardiovascular therapy. PMID: 18187671
CD47 in the immune response: role of thrombospondin and SIRP-alpha reverse signaling. PMID: 18855618
CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. PMID: 29288236
Elimination of donor CD47 protects against vascularized allograft rejection in mice. PMID: 30136356
CD47 applies the brakes to angiogenesis via vascular endothelial growth factor receptor-2. PMID: 21191182
Targeting CD47: NO limit on therapeutic potential. PMID: 17363705
CD47 checkpoint data supercharge Stanford spinout IPO. PMID: 30080839
The use of CD47-modified biomaterials to mitigate the immune response. PMID: 27190273
Blocking thrombospondin-1 signaling via CD47 mitigates renal interstitial fibrosis. PMID: 32366943
The CD47-SIRPalpha signalling system: its physiological roles and therapeutic application. PMID: 24627525
CD47 promotes cell growth and motility in epithelial ovarian cancer. PMID: 31493748
Anti-CD47 Agent Boosts Macrophage Activity in NHL. PMID: 30464001
Selective CD47 targeting with a bispecific antibody. PMID: 33388996
[Role of CD47 in hematologic malignancies]. PMID: 24370062
Relationship between tumor-associated macrophage subsets and CD47 expression in squamous cell carcinoma of the head and neck in the tumor microenvironment. PMID: 27322955
CD47 Blocking Antibody Accelerates Hematoma Clearance After Intracerebral Hemorrhage in Aged Rats. PMID: 31664629
Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity. PMID: 32761423
CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis. PMID: 31689243
The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications. PMID: 22310103
CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration. PMID: 33389016
CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer. PMID: 27411490
Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRP axis. PMID: 31183992
The overall potential of CD47 in cancer immunotherapy: with a focus on gastrointestinal tumors. PMID: 31686549
The interaction between signal regulatory protein alpha (SIRPalpha) and CD47: structure, function, and therapeutic target. PMID: 24215318
Exosome-SIRPalpha, a CD47 blockade increases cancer cell phagocytosis. PMID: 28086180
Upregulation of CD47 Is a Host Checkpoint Response to Pathogen Recognition. PMID: 32576678
CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. PMID: 19632179
Epithelial CD47 is critical for mucosal repair in the murine intestine in vivo. PMID: 31676794
CD47 Protects Synapses from Excess Microglia-Mediated Pruning during Development. PMID: 30308165
Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. PMID: 31771616
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. PMID: 22451913
Just eat it: A review of CD47 and SIRP-alpha antagonism. PMID: 32517874
Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. PMID: 32929084
Is CD47 an innate immune checkpoint for tumor evasion? PMID: 28077173
Role of CD47 in Hematological Malignancies. PMID: 32677994
Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience. PMID: 29994903
CD47 signaling pathways controlling cellular differentiation and responses to stress. PMID: 25708195
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. PMID: 26322579
CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. PMID: 27437576
Blocking "don't eat me" signal of CD47-SIRPalpha in hematological malignancies, an in-depth review. PMID: 29709247
CD47: the next checkpoint target for cancer immunotherapy. PMID: 32535479
CD47: role in the immune system and application to cancer therapy. PMID: 31485984
The CD47-SIRPalpha signaling axis as an innate immune checkpoint in cancer. PMID: 28258703
Advances in Anti-Tumor Treatments Targeting the CD47/SIRPalpha Axis. PMID: 32082311
The CD47-SIRPalpha Immune Checkpoint. PMID: 32433947
SIRPalpha-CD47 Immune Checkpoint Blockade in Anticancer Therapy. PMID: 29336991
For research use only. Not for human or drug use.
